|
UCB to File for Two More Cimzia Arthritis Indications This Year, Tables Another RA Candidate
UCB plans to submit marketing applications for Cimzia in psoriatic arthritis and axial spondyloarthritis (AxSpA), including ankylosing spondylitis, to the FDA and EU by the end of the year.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives